We need to take inspiration from the progress in oncology over the last few decades and challenge ourselves to adapt its successful playbook to mental illness. It’s time for precision psychiatry.
Delix Therapeutics is developing drugs that offer the therapeutic benefits of psychedelic drugs, but without the hallucinations and other side effects that accompany these compounds. The startup has closed $70 million in Series A financing as it works to bring its lead candidates into the clinic next year.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.